Trial Profile
A double-blind, randomized, active- and placebo-controlled four-way crossover trial to evaluate the abuse potential of IV CR845 in non-dependent, recreational polydrug users with lifetime and recent hallucinogenic drug use
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2016
Price :
$35
*
At a glance
- Drugs Difelikefalin (Primary) ; Pentazocine
- Indications Pain
- Focus Adverse reactions
- Sponsors Cara Therapeutics
- 03 Nov 2016 According to a Cara Therapeutics media release, the data from this trial presented at PAINWeek and the Orthopaedic Trauma Association 2016 Annual Meeting
- 31 May 2016 According to a Cara Therapeutics media release, the results from this trial will be presented at the International Conference on Opioids.
- 10 Mar 2016 According to a Cara Therapeutics media release, data from this study was presented at the American Academy of Pain Medicine's 32nd Annual Meeting in February 2016.